- Home
- ABEO vs IMRX Comparison
ABEO vs IMRX Comparison
Compare ABEO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | IMRX |
|---|---|---|
| Founded | 1974 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.5M | 232.3M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABEO | IMRX |
|---|---|---|
| Price | $2.28 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $18.38 | $17.00 |
| AVG Volume (30 Days) | ★ 1.7M | 752.9K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $731.38 | N/A |
| Revenue Next Year | $129.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $2.30 | $3.35 |
| 52 Week High | $7.65 | $8.48 |
Technical Indicators
Market Signals| Indicator | ABEO | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 17.41 | 49.87 |
| Support Level | N/A | $3.38 |
| Resistance Level | $5.77 | $4.16 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | -0.19 | 0.03 |
| Stochastic Oscillator | 2.26 | 56.52 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.